#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cystic fibrosis Herpes simplex Small cell lung cancer extensive stage Retinopathy of prematurity Mitochondrial DNA depletion Hereditary optic atrophy Neuroendocrine tumour of the lung Frontotemporal dementia Chronic myeloid leukaemia (in remission) Hodgkin's disease Canavan disease Scedosporium infection ABO haemolytic disease of newborn Mucopolysaccharidosis II Osteomyelitis More trials…

    Learn about Rare Diseases

    Piriformis syndrome – Diagnostics Myelodysplastic syndrome – Life with Disease Epidermolysis bullosa – Life with Disease Alagille syndrome – Basic Information Ewing’s sarcoma – Treatment Primary biliary cholangitis – Basic Information Atypical haemolytic uraemic syndrome – Trials in Disease Leukoencephalopathy – Life with Disease Myelodysplastic syndrome with excess blasts – Trials in Disease Hereditary optic atrophy – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Trimetazidine Dihydrochloride Omo-103 SPY002 Polydextrose ABBV-8736 Hmb-001 68Ga-Nota-Abscint-Her2 Carbamazepine Iptacopan Alirocumab Digitoxin Ferric Carboxymaltose Copper (64Cu) Chloride VERCIRNON Eprosartan Mesilate Pemetrexed Diacid Monohydrate Venetoclax Remifentanil Hydrochloride Ciclesonide Elasomeran More therapies…

    Learn about Your Condition

    Diabetic nephropathy Polymyositis Osteopenia Ankylosing spondylitis Meniere's disease Bladder cancer recurrent Malignant neoplasm of choroid Procedural headache Breast cancer in situ Indolent systemic mastocytosis Alport's syndrome Behcet's syndrome Ichthyosis Endocarditis Autoimmune disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centrum Medyczne Dietla 19 Sp. z o.o.

Centrum Medyczne Dietla 19 Sp. z o.o.

Ul. Jozefa Dietla 19/3, Cracow, 31-070, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Age-related macular degeneration
    Investigated Drugs:
    • Aflibercept
    Estonia Germany Latvia Poland Spain

  • FWY003 in Geographic Atrophy Secondary to Age-Related Macular Degeneration in Patients

    Recruiting

    2 1
    Investigated Diseases:
    • Dry age-related macular degeneration
    Bulgaria Czechia France Germany Hungary Italy +3

  • A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Aflibercept
    Bulgaria Czechia Hungary Latvia Poland Slovakia

  • Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

    Recruiting

    2 1
    Investigated Drugs:
    • XELAFASLATIDE
    Austria Czechia Germany Greece Hungary Italy +3

  • Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

    Recruiting

    2 1
    Czechia Germany Hungary Poland Slovakia

  • Safety and Efficacy of Two Doses of OCUL101 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

    Not yet recruiting

    4 1 1 1
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Latvia Poland

  • Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Choroidal neovascularisation
    Investigated Drugs:
    • Faricimab
    • Ranibizumab
    France Germany Italy Poland Spain

  • Study on the Use of SB11 Pre-Filled Syringe for Patients with Wet Age-Related Macular Degeneration, Macular Edema from Retinal Vein Occlusion, or Myopic Choroidal Neovascularization

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Choroidal neovascularisation
    • Macular oedema
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Ranibizumab
    Poland

  • Study of Atropine Sulfate eye drops (0.

    Not recruiting

    3 1
    Investigated Diseases:
    • Myopia
    Investigated Drugs:
    • Atropine Sulfate
    Hungary Ireland Poland Slovakia Spain

  • Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Vascular Endothelial Growth Factor Receptor 3 Extracellular Domains 1-3 Fused To A Igg1 Fc Fragment
    • Ranibizumab
    Czechia Denmark France Germany Greece Hungary +4
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!